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Oncostatin m Impairs Brown Adipose Tissue
Thermogenic Function and the Browning
of Subcutaneous White Adipose Tissue
David Sanchez-Infantes1*, Ruben Cereijo2,3,4*, Marion Peyrou2,3,4, Irene Piquer-Garcia1,
Jacqueline M. Stephens5, and Francesc Villarroya2,3,4
Objective: Since oncostatin m (OSM) is elevated in adipose tissue in conditions of obesity and type 2
diabetes in mice and humans, the aim of this study was to determine whether this cytokine plays a cru-
cial role in the impairment of brown adipose tissue (BAT) activity and browning capacity that has been
observed in people with obesity.
Methods: C57BL/6J mice rendered obese by high-fat diet, their lean controls, and C57BL/6J mice fed a
standard diet and implanted subcutaneously with a mini pump through a surgical procedure to deliver
OSM or placebo were used. Preadipocytes or fully differentiated brown adipocytes were treated with
OSM or vehicle with or without norepinephrine before harvesting. RNA was extracted and processed for
qPCR analysis. Media from mature adipocytes was also collected to measure glycerol levels.
Results: Studies demonstrated that OSM gene expression was increased in BAT of mice fed a high-fat
diet. In addition, exogenous OSM impaired BAT activity and the browning capacity of white adipose tis-
sue in vitro and in vivo.
Conclusions: Overall, the results reveal a negative role for OSM on BAT and on the browning of white
adipose tissue. Therefore, further studies are necessary to demonstrate whether OSM inhibition is a
potential treatment for metabolic disorders.
Obesity (2017) 25, 85-93. doi:10.1002/oby.21679
Introduction
Oncostatin m (OSM) is a gp130 cytokine that shares substantial
sequence identity with leukemia inhibitory factor (1) and can modu-
late a variety of biological processes such as liver development and
regeneration (2,3), hepatic insulin resistance and steatosis (4),
inflammation (5), and cardiomyocyte dedifferentiation and remodel-
ing (6). However, unlike other gp130 cytokines, OSM has its own
specific receptor, OSMR, that heterodimerizes with gp130 (7) and
mediates the majority of OSM actions. Recently, we demonstrated
that OSM is produced in white adipose tissue (WAT) under obese
conditions in mice and humans and has proinflammatory roles on
adipocytes (8). Moreover, we reported that OSM was not detectable
in adipose tissue of healthy lean human subjects but was elevated in
patients with obesity where adipose tissue OSM protein levels
directly correlated with body mass index and insulin resistance (8).
The increased risk of breast cancer associated with obesity has been
widely reported, and the key mechanisms linking the obese state
with cancer etiology are being actively investigated (9). Recently, it
has been shown that OSM is secreted by stromal vascular cells in
breast adipose tissue, and its inhibition by neutralizing antibody in
animal models of breast cancer led to various improvements, includ-
ing decreased peri-tumoral angiogenesis and cellular scattering (10).
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In addition to breast cancer, elevated OSM levels have been associ-
ated with many other types of cancers including ovarian cancer,
Ewing sarcoma, and prostate cancer (11).
Obesity is the primary disease involving fat cells, but obesity is also a
major risk factor for the development of serious and costly diseases
such as type 2 diabetes mellitus (T2DM), cardiovascular disease,
hypertension, and metabolic syndrome. Disruption of adipose tissue
expansion can lead to altered adipokine secretion and profoundly con-
tribute to the development of metabolic diseases (12). In obesity asso-
ciated with metabolic inflammation, there is a continual state of
chronic low-grade inflammation in adipose tissue that is characterized
by the presence of various proinflammatory immune cells (13) that
secrete inflammatory cytokines, in conditions of obesity and T2DM.
Similar to TNF and IL-6, OSM is an immune cell-derived cytokine in
WAT where it promotes metabolic dysfunction. Understanding the
cross talk between immune cells and adipocytes and their contribution
to obesity and insulin resistance is an important area of investigation.
The amount and activity of brown adipose tissue (BAT) and the brown-
ing of subcutaneous WAT (appearance of thermogenic beige/brite adi-
pocytes in WAT depots) have been associated with protection against
obesity and improvement of associated metabolic alterations (14).
These effects of BAT are traditionally attributed to its capacity to oxi-
dize fatty acids and glucose to sustain thermogenesis. However, BAT,
similar to WAT, has also been recognized to secrete endocrine factors
with potential beneficial effects on metabolism referred to as “brown
adipokines “or “batokines” (14). Until recently, it was largely accepted
that, in humans, BAT only exists in children and disappears with age,
but positron emission tomography scanning has revealed the existence
of active BAT in adults (15,16). Moreover, most of the adult BAT is
derived from WAT cells that could potentially acquire the beige/brite
thermogenic phenotype. The possibility of converting energy-storing
white adipocytes into energy-consuming beige/brite fat cells is a rele-
vant topic in current research to achieve protection against obesity and
the associated metabolic alterations (17-19).
Some recent studies have documented metabolically beneficial effects of
OSM on adipocytes and glucose tolerance (20-22). However, the major-
ity of studies have supported a role of OSM to promote metabolic dys-
function (4,8,23). To further understand the actions of OSM in metabolic
disease states, we examined the ability of OSM to modulate BAT and
the browning of WAT. Our novel studies revealed that both in brown
and white adipocytes, OSM is able to impair both BAT activity and the
browning process and to affect thermogenic gene expression, adipokine
secretion, insulin sensitivity, and glucose and lipid metabolism.
Methods
Mice
Animals used in this study (n 5 4–8) included C57BL/6J mice either
rendered obese by high-fat diet (HFD) alongside their lean controls
(Jackson Laboratories) or mice (Charles River) fed a standard diet
and implanted subcutaneously with micro-osmotic pumps. The HFD
used contained 60% kcal from fat (Research Diets Inc; D12492).
Control diet contained 10% kcal from fat (Research Diet Inc.;
D12450B). Both diets contained 10% kcal from protein with the bal-
ance in caloric intake provided by differences in carbohydrate con-
tent. HFD feeding began on 6-week-old mice and extended until
their sacrifice after 12 weeks. Tissues were collected for total RNA,
protein, or microscopy analysis.
Micro-osmotic pumps (Alzet 1007D, Charles River) were surgically
implanted subcutaneously over interscapular BAT or adjacent to
inguinal WAT (iWAT) to deliver OSM at a dose of 12 ng/g of
mouse weight per day or PBS during 7 days. Mice used in this
experiment were kept at basal conditions (218C, ambient tempera-
ture). Since these animals were not at thermoneutrality, it is
expected that the BAT from control and treated mice was in an acti-
vated condition required to examine the ability of OSM to down-
regulate BAT activity. In iWAT-implanted mice, animals were
placed in a cold environment (48C) to induce browning (24). Animal
care and use was approved by the Institutional Animal Care and
Use Committee at Pennington Biomedical Research Center and the
European Community Council Directive 86/609/EEC. All experi-
mental procedures were approved by the Institutional Animal Care
and Use Committee of the University of Barcelona.
Cell culture
Immortalized BAT preadipocytes from C57BL/6J mice (25) were
grown in DMEM supplemented with 10% fetal bovine serum (FBS)
and 1% penicillin/streptomycin (P/S) (Life Technologies). Upon
reaching confluence, a differentiation cocktail containing 0.5 mmol/
L 3-isobutyl-methylxanthine (IBMX), 1 lmol/L dexamethasone,
insulin (20 nM), and T3 (1 nM) was used to induce differentiation
as previously described (25). Cells were maintained in this medium
for 8 days until they became fully differentiated. Preadipocytes or
fully differentiated brown adipocytes were treated with 1 nM mouse
recombinant OSM (R&D Systems) or vehicle with or without 0.5
lM norepinephrine (NE) before harvesting. RNA was extracted and
processed for qPCR analysis. Media from mature adipocytes was
also collected to measure free glycerol levels (FG0100 kit, Sigma).
RNA and protein isolation
Epididymal WAT (eWAT), iWAT, and interscapular BAT were col-
lected in liquid nitrogen. Samples from BAT and iWAT were fixed in
4% formaldehyde as well to perform hematoxylin-eosin staining. Total
RNA was extracted from tissue or harvested cell cultures using a
column-affinity based methodology (NucleoSpin RNA II; Macherey-
Nagel, D€uren, Germany). RNA yield was determined by spectropho-
tometry (NanoDrop). 500 ng of total RNA were retrotranscribed into
cDNA using random hexamer primers and Multiscribe reverse tran-
scriptase (TaqMan reverse transcription reagents, Thermo Fisher Scien-
tific), following the manufacturer’s instructions. Platinum Quantitative
PCR SuperMix-UDG with ROX reagent (Themo Fisher) was used as
master mix reagent and expression levels of each gene of interest were
assessed with the following specific TaqMan probes (Thermo Fisher):
Osm (Mm01193966_m1), Osmr (Mm01307326_m1), monocyte che-
moattractant protein-1 (Ccl2) (Mm00441242_m1), uncoupled protein 1
(Ucp1) (Mm00494069_m1), peroxisome proliferator-activated recep-
tor-gamma coactivator (Pgc1a) (Mm00447183_m1), perilipin 1 (Plin1)
(Mm00558672_m1), hormone sensitive lipase (Lipe) (Mm00495359_
m1), fatty acid synthase (Fas) (Mm00662319_m1), fibroblast
growth factor 21 (Fgf21) (Mm00840165_g1), beta Klotho (Klb)
(Mm00473122_m1), interleukin 6 (Il-6) (Mm00446191_m1), T-box 1
(Tbx1) (Mm00448949_m1), Leptin (Lep) (Mm00434759_m1),
tumor necrosis factor-alpha (Tnfa) (Mm00443258_m1) and 18S
(Hs99999901_s1). Relative expression of each mRNA was quantified
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using the ABI 7500 Real-Time PCR System (Themo Fisher). Transcript
levels were normalized to that of housekeeping gene 18S. For protein
analysis, tissues were homogenized in a buffer containing 10 nmol/L
HEPES, 5 mmol/L ethylendiamine tetraacetic acid, 5 mmol/L dithio-
threitol, and 5 mmol/L MgCl2 supplemented with protease inhibitors
(Complete-mini, Roche). Total protein was measured by Ponceau stain-
ing. Interleukin-6, insulin, leptin, total plasminogen activator inhibitor-1
(PAI-1), resistin and OSM were measured using a MILLIPLEXVR MAP
Mouse Metabolic Disease Multiplex Assay (Luminex 200TM, Millipore
Corporation, MADKMAG-71K and MCVD2MAG-77K, respectively).
Statistical analysis
Results are expressed as mean 6 SEM. Differences between specified
groups were analyzed using the two-tailed Student’s t-test. A P value
of less than 0.05 was considered statistically significant. Hematoxylin-
eosin staining quantification of adipocytes was performed on the
Image J Software Suite.
Results
Osm and Osmr mRNA expression are increased
in BAT from mice following HFD
The mRNA levels of Osm were increased and the mRNA levels of its
specific receptor Osmr did not change significantly (despite a
tendency to be increased) in BAT from mice fed a HFD for 12 weeks
(Figure 1). These mice also showed a decrease in Ucp1 and a non-
significant trend of lower levels of Pgc1a and Pparg mRNA (Figure
1). As expected, we observed a significant increase in mRNA levels
of Tnf and Ccl2 in BAT from mice fed a HFD for 12 weeks compared
with the control group (1.5 6 0.2 vs. 3.7 6 0.3, n 5 7, P 5 0.077, and
1.3 6 0.2 vs. 3.3 6 0.9, n 5 7, P 5 0.041, respectively; arbitrary units
relative to 18S rRNA), confirming the expected inflammation and the
reduction of thermogenic activity of BAT with HFD.
OSM affects inflammatory state and lipid
homeostasis in BAT
In order to determine the action of OSM on BAT, micro-osmotic
pumps were placed adjacent to interscapular BAT to deliver vehicle
or OSM for 1 week in vivo. As shown in Figure 2, we observed a
decrease in the mRNA expression of Fgf21 and Bmp8b in BAT, as
compared with mice receiving vehicle. Although OSM induced a
decrease in BAT Fgf21 mRNA levels, there were no substantial
changes in circulating levels of FGF21 (Figure 2B). In addition, no
changes in the expression of transcripts for the thermogenic markers
Ucp1, Pgc1a, or Pparg were observed. Increased mRNA expression
for genes encoding inflammatory cytokines including Tnf, Ccl2, and
Il-6 was observed in BAT following OSM administration (Figure
2C). A histological analysis revealed that OSM treated mice had
decreased lipid storage in BAT (Figure 2D) and mice receiving
Figure 1 OSM mRNA levels are elevated in BAT from mice fed HFD for 12 weeks. Relative mRNA abundance was assessed in BAT from mice fed
HFD or normal diet for 12 weeks to measure Osm, Osmr, Tnf, Ccl2, Ucp1, Pgc1a, and Pparg. Data were normalized to 18S, and differences were
determined via Student’s t-test where a P value of <0.05 was considered significant. n 5 8. *P< 0.05.
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Figure 2 Administration of exogenous OSM to BAT by osmotic micro-pump impairs the mRNA expression of genes involved in BAT
activity and produces an inflammatory state. (A) Fgf21 and Bmp8b mRNA levels were decreased in BAT from C57/Bl6 mice receiv-
ing OSM for 1 week by osmotic delivery systems (micro-osmotic pumps) in BAT at room temperature. Relative mRNA levels were
assessed in BAT from mice receiving OSM or PBS for 1 week to measure Ucp1, Fgf21, Klb, and Bmp8b. n 5 8. (B) FGF21 circulat-
ing levels were similar in BAT from C57/Bl6 mice receiving OSM for 1 week on BAT by osmotic delivery systems (micro-osmotic
pumps) at room temperature. (C) Tnf, Ccl2, and Il-6 mRNA levels were increased in BAT from C57/Bl6 mice receiving OSM for
1 week on BAT by osmotic delivery systems (micro-osmotic pumps) at room temperature. Relative mRNA levels were assessed in
BAT from mice receiving OSM or PBS for 1 week to measure Tnf, Ccl2, and Il-6. n 5 8. (D) BAT hematoxylin–eosin staining from
C57/Bl6 mice after 1 week of treatment with micro-osmotic pumps filled with buffer control or OSM on BAT. (E) Srebf1, Plin1, Lipe,
and Fasn mRNA levels were decreased in BAT from C57/Bl6 mice receiving OSM for 1 week on BAT by osmotic delivery systems
(micro-osmotic pumps) at room temperature. Relative mRNA levels were assessed in BAT from mice receiving OSM or PBS for 1
week (n 5 8) to measure Srebf1, Plin1, Lipe, and Fasn. All the mRNA data were normalized to 18S, and differences were deter-
mined via Student’s t-test where a P value of <0.05 was considered significant. *P< 0.05; **P< 0.01. [Color figure can be viewed
at wileyonlinelibrary.com]
OSM had decreased mRNA levels of lipid homeostasis genes such
as Srebf1, Fasn, Lipe, and Plin1 (Figure 2E). The expression of
Fgf21, Klb, Ucp1, Pparg, or Tbx1 was not altered in iWAT (data
not shown). The level of expression of Ccl2 and Tnf was also simi-
lar in both groups in inguinal adipose tissue (data not shown). How-
ever, decreased levels of leptin and increased levels of IL-6 in serum
were also observed in OSM treated mice (Table 1). Measurement of
Lep transcript levels revealed a significant reduction both in BAT
(n 5 7, P 5 0.041) and WAT (n 5 7, P 5 0.0001). OSM protein lev-
els were not detected in serum or adipose depots of the mice after
1 week of delivering by micro-osmotic pump located in BAT. Col-
lectively, our results demonstrate that OSM expression can affect
both the lipid metabolism and the inflammatory state of BAT. How-
ever, targeted delivery of OSM to BAT did not have a direct impact
on distant organs such as iWAT.
OSM negatively impacts browning of iWAT
following cold exposure
To assess the actions of OSM on the process of browning of iWAT,
mice were fed a standard diet and a mini pump delivering PBS or
OSM was inserted directly adjacent to iWAT. Following placement of
mini pumps, mice were exposed to cold for 1 week to further activate
thermogenesis pathways. Histological analysis revealed the presence
of brown-like (multilocular) adipocyte accumulation in iWAT follow-
ing cold exposure. Moreover, significantly larger white adipocytes
were found in the iWAT from mice treated with OSM compared with
the control group (Figure 3A). The quantification of brown-like adipo-
cyte accumulation showed a decrease in iWAT of mice receiving
OSM (71.5% of multilocular adipocytes in control group vs. 25.3% in
OSM treated mice) (Figure 3B). The area of unilocular adipocytes was
significantly higher in mice treated with OSM compared with the con-
trol group (Figure 3B). In addition, mice implanted with OSM-
delivering micro-osmotic pumps to iWAT exhibited lower levels of
Ucp1 mRNA (Figure 3C) but this effect did not reach statistical signif-
icance (P 5 0.081). Similar levels of Pgc1a were observed in both
conditions. A marked decrease in Tbx1 and an increase in Glut4
expression were observed in iWAT of OSM treated mice. In addition,
the mRNA levels of Ccl2 and Tnf were similar in both groups (Figure
3D). A histological analysis of the BAT from these mice did not indi-
cate any profound differences after cold exposure between control
mice and those with OSM delivery to iWAT (Figure 4A). Also, no
substantial changes in Ucp1 mRNA in BAT were observed between
control and iWAT OSM treatment. A clear and significant increase in
the mRNA levels of Pgc1a, Pparg, Fgf21, and Bmp8b was observed
in the BAT of the iWAT OSM treated group (Figure 4B). Circulating
levels of FGF21 were unchanged (data not shown) and no significant
differences in Tnf and Il-6 mRNA levels were observed in BAT
(Figure 4B). OSM protein levels were not detected in serum or adipose
depots after 1 week of OSM delivery by micro-osmotic pump located
in iWAT.
OSM reduces brown adipocyte
differentiation in vitro
C57Bl6 preadipocytes were differentiated into brown adipocytes as
previously described (25). Exposure to OSM throughout the differ-
entiation process resulted in a reduction in the number of differenti-
ated adipocytes as assessed by microscopy morphology (lipid vacuo-
lae accumulation) (Figure 5A). Consistent with these observations,
we also observed lower mRNA levels of Pgc1a in OSM treated cells
as compared with the control group after 10 days (Figure 5B). We
also examined the effects of OSM on fully differentiated brown adi-
pocytes and on their responsiveness to the thermogenic activator
NE. As expected, NE treatment of mature brown adipocytes resulted
in an increase in the expression of Ucp1 and Pgc1a mRNA levels.
The incubation of brown adipocytes with OSM significantly reduced
the basal expression of Ucp1, Pgc1a, and Pparg transcripts and also
impaired the ability of NE to induce several genes including Ucp1
and Pgc1a (Figure 5C). Free glycerol concentrations in media from
mature brown adipocytes were similar in the vehicle and OSM
treated groups suggesting no significant alterations in lipolysis (data
not shown). As expected, NE treatment increased glycerol levels,
but the presence of OSM did not alter NE-induced glycerol hydroly-
sis in these adipocytes (data not shown).
Discussion
Increased BAT recruitment and activation have been linked to
improvements in energy balance and glucose and lipid metabolism
(26). Moreover, the browning capacity of subcutaneous iWAT has











OSM 6 SEM P
Insulin (ng/mL) 1.06 6 0.15 1.23 6 0.11 0.416 1.47 6 0.19 1.14 6 0.10 0.136
TAG (mg/dL) 153 6 15.48 117.75 6 15.94 0.148 162.25 6 5.92 157.83 6 10.49 0.758
Leptin (ng/mL) 2.14 6 0.45 0.54 6 0.12 0.005** 0.77 6 0.15 0.69 6 0.13 0.726
Total PAI-1 (ng/mL) 1.78 6 0.33 1.97 6 0.35 0.728 0.81 6 0.19 1.78 6 0.33 0.097
IL6 (pg/mL) 8.60 6 2.38 29.81 6 8.78 0.028* 19.67 6 3.56 12.96 6 3.56 0.279
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also been associated with improvements in metabolic function (9).
Some studies have also reported an impairment of BAT function
under inflammatory conditions (27,28). However, the role of OSM
in BAT and browning activity has not been previously studied. Our
novel observations demonstrate that OSM can impair BAT differen-
tiation and function and can alter iWAT browning capacity in vitro
and in vivo.
We previously reported that OSM is secreted by macrophages pres-
ent in WAT and that OSM expression is increased in epididymal
WAT of mice fed a HFD (8). In this study, we demonstrate that
OSM is also increased in BAT of mice fed a HFD. In addition, the
presence of OSM is strongly correlated with parameters associated
with reduced BAT activity. To further analyze the effects of OSM
on BAT in vivo, we subcutaneously implanted micro-osmotic pumps
adjacent to BAT in mice to locally administer a constant dose of
OSM. The animals were housed at 218C and therefore there was
some BAT activation under these experimental conditions (26); it
allowed us to examine the potential repressive effects of OSM on
BAT function that would had not been feasible with mice at thermo-
neutrality, a condition where BAT activity is suppressed.
OSM exposure induced a significant decrease in the expression of
Fgf21 and Bmp8b mRNA in BAT. Both FGF21 and BMP8b are fac-
tors secreted by BAT with important roles in glucose metabolism,
browning, and improvements in metabolic status (25,29,30). How-
ever, we did not observe changes in other thermogenic genes in
brown fat following OSM treatment. In addition, the OSM delivered
to BAT produced a significant increase in the expression of inflam-
matory markers such as Tnf, Ccl2, Il-6, and Il-18. These data sug-
gest that OSM changes BAT paracrine functions by preventing the
release of prothermogenic signals while inducing the release of
BAT-deleterious proinflammatory cytokines. These observations are
highly consistent with proinflammatory actions of OSM on adipo-
cytes and WAT (8,10) as well as on bone marrow cells (31). More-
over, histological analysis of BAT revealed that OSM induced an
altered brown adipocyte structure associated with a reduction in
lipid droplet-containing cells. We observed decreased expression of
Plin1, Lipe, and Fasn in BAT from OSM treated mice that was con-
sistent with our histological observations. The decreased leptin
serum levels was consistent with the reduced expression of leptin in
BAT and WAT that we observed in our experimental setting of
OSM delivery to BAT. Considering the minor contribution of BAT
to systemic leptin levels (32), it is possible that alterations in BAT
secretory function, such as those noted above, may influence other
tissues including WAT and its leptin secretion capacity.
Our observations are not consistent with studies that have indicated
a metabolically favorable role for OSM in obesity (20-22). This
apparent discrepancy may be a result of the very high doses of
OSM used in those studies. In our study, the mice received a dose
of OSM that was calculated to be delivered daily (12 ng/g of weight
of mouse) for 1 week, which is less than the dose administrated by
other groups. Presumably, OSM bound to its specific receptor pres-
ent in brown adipocytes and produced the observed effects. It is not
surprising to us that the levels of OSM were very undetectable in
tissues and serum since our study was performed in lean mice. Also,
cytokines such as OSM are labile and are typically internalized and
degraded after receptor engagement.
In addition to evaluating the capability of OSM to affect the browning
process, micro-osmotic pumps constantly releasing OSM were
implanted in the subcutaneous iWAT of mice and they were cold
exposed to initiate the process of browning (24). OSM treatment
Figure 3 Administration of exogenous OSM to iWAT by osmotic micro-pump decreases the browning percentage in mice exposed to cold temperature for 1
week. (A) iWAT hematoxylin–eosin staining from C57/Bl6 mice receiving OSM or PBS for 1 week by osmotic delivery systems (micro-osmotic pumps) in
iWAT at cold temperature. (B) The percentage of multilocular adipocytes was lower in iWAT from C57/Bl6 mice receiving OSM for 1 week by osmotic deliv-
ery systems (micro-osmotic pumps) in iWAT at cold temperature. This group also showed larger white adipocytes compared with the PBS group. (C) Tbx1
mRNA levels were decreased in iWAT from C57/Bl6 mice receiving OSM for 1 week by osmotic delivery systems (micro-osmotic pumps) in iWAT at cold
temperature, while Glut4 was increased. Ucp1, Pgc1a, Fgf21, and Klb mRNA levels were unchanged. (D) No changes in inflammatory markers were
detected in this tissue. Relative mRNA levels were assessed in sWAT from C57/Bl6 mice receiving OSM or PBS for 1 week by osmotic delivery systems
(micro-osmotic pumps) in iWAT at cold temperature (n 5 8) to measure Ucp1, Pgc1a, Tbx1, Fgf21, Klb, Glut4, Tnf, Ccl2 and Il-6. All the mRNA data were
normalized to 18S, and differences were determined via Student’s t-test where a P value of <0.05 was considered significant. *P< 0.05. [Color figure can
be viewed at wileyonlinelibrary.com]
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decreased the mRNA levels of Tbx1, a specific gene related to the
presence of beige fat (33). Moreover, analysis of subcutaneous WAT
revealed fewer browning areas in the mice receiving OSM (71.5% of
multilocular adipocytes in control group vs. 25.3% in mice receiving
OSM) and larger white adipocyte area, corroborating the hypothesis
that increased OSM impairs the iWAT browning process, inhibits
brown/beige adipogenesis, and appears to promote hypertrophy of adi-
pocytes. The increased expression of glucose transporter Glut4 in
Figure 4 Response of BAT to OSM delivered by osmotic micro-pump to iWAT. (A) BAT hematoxylin–eosin staining from C57/Bl6 mice
receiving OSM or PBS for 1 week by osmotic delivery systems (micro-osmotic pumps) in iWAT at cold temperature. (B) Pgc1a,
Pparg, Fgf21, and Bmp8b mRNA levels were increased in BAT from C57/Bl6 mice receiving OSM for 1 week by osmotic delivery sys-
tems (micro-osmotic pumps) in iWAT at cold temperature, while Ucp1 mRNA levels were not changed. Relative mRNA levels were
assessed in BAT from C57/Bl6 mice receiving OSM or PBS for 1 week by osmotic delivery systems (micro-osmotic pumps) in iWAT
at cold temperature n 5 8 to measure Ucp1, Pgc1a, Pparg, Fgf21, Tnf, IL-6, and Bmp8b. All the mRNA data were normalized to
18S, and differences were determined via Student’s t-test where a P value of <0.05 was considered significant. *P<0.05;
***P< 0.001. [Color figure can be viewed at wileyonlinelibrary.com]
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OSM-administered animals possibly reflects enhanced glucose uptake
to sustain lipogenesis and lipid droplet enlargement in this condition.
Activation of thermogenesis in BAT and brown/brite adipocytes pres-
ent in WAT has been shown to contribute to the control of body
weight and glucose homeostasis, owing to the high capacity of brown
adipocytes to oxidize fatty acids and glucose (14,26). Therefore, it is
conceivable that the excess OSM secreted by macrophages and T cells
present in WAT and BAT could contribute to the development of obe-
sity and insulin resistance by inhibiting brown adipocyte differentia-
tion and thermogenic function.
In mice receiving OSM in iWAT, we found signs of BAT thermo-
genic activation, whereas iWAT showed impaired browning. The
repression of iWAT browning is likely to be due to the direct effects
of OSM whereas BAT activation may occur as a compensatory pro-
cess, reactive to iWAT browning impairment. This scenario has
been previously found in other animal models where inhibition of
iWAT browning occurred (30). Conversely, a lack of BAT has been
associated with the induction of browning in iWAT, also consistent
with a compensatory mechanism to maintain energy expenditure
homeostasis (34-36).
Cell-autonomous effects of OSM on brown adipocytes did not indicate
any positive effects on thermogenic activation, but the opposite. When
brown preadipocytes were incubated with OSM, we observed a clear
impairment in brown adipocyte differentiation as shown by decreased
lipid accumulation and decreased expression of Pparg and Pgc1a
expression. OSM treatment of fully differentiated brown adipocytes
reduced the expression of the thermogenic genes Ucp1 and Pgc1a and
blunted their induction by NE, a thermogenic mediator. However,
OSM was not able to decrease the glycerol levels in the media, indi-
cating a lack of direct functional effect on lipolysis. These data dem-
onstrate that OSM is able to act on brown adipocytes and is associated
with reduction in BAT thermogenic activation and differentiation.
Overall, our results reveal a novel negative role for OSM on BAT acti-
vation and on the browning process of iWAT. Since OSM is elevated
in obesity and T2DM in mice and humans (8), this cytokine may also
mediate its effect by playing a role in the impairment of BAT abun-
dance and the reduced browning capacity reported in people with obe-
sity (37,38). Future studies are merited to determine whether inhibition
of OSM is a suitable target for treatment of metabolic disorders.O
VC 2016 The Obesity Society
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